Vaccines have been evaluated for many years in patients with melanoma with few long-term reports. Doctors at the University of Oklahoma recently reported results of a vaccine trial with at least 5 years follow-up. One hundred twenty-nine patients with stage I and II melanoma were treated after surgical removal of the cancer with a unique vaccine that is a subcellular tumor homogenate.

Stage I patients had an 87.5% and stage II patients had a 64% 5-year survival rate. These doctors compared their results with those of patients previously treated with surgery alone. They concluded that the vaccine benefited patients with stage II disease, those with 2-4 positive lymph nodes, and those with 5 or more positive lymph nodes. However, large scale testing of a standardized vaccine will be very difficult to carry out. (Journal of Surgical Oncology, Vol 47, No 4, pp 233-238, 1991)

Copyright © 2018 CancerConnect. All Rights Reserved.

Recommended Articles

Image placeholder title

What Should Women Know About Bladder Cancer

Michael O’Donnell, MD Director of Urologic Oncology, University of Iowa Hospitals and Clinics

Green Background CC CancerConnect

Liquid Biopsy Detects Disease Progression Much Earlier Than Imaging

What if a simple blood test could quickly determine when chemotherapy was ineffective and prevent its unnecessary use?